Alright, just please leave a note if you have to be away for an extended period, and I will set my timeout interval accordingly. And thanks for resuming discussion!
But I don’t recall posting excerpts or referring to essays in my previous comments to you, I do recall going through your essay and presenting my points in reply.
Alright again, the forum here doesn’t seem to have a good search function, so I’ll just take a fresh run at this.
Now first of all, I think this post depicts more accurately what Axe did than this essay on Panda’s Thumb. Axe wasn’t trying to measure part of the base of the wild-type enzyme, he was trying to evaluate the whole peak of the partially-disabled enzyme, as you depict in the former post. So I’ll address the former post, not the latter article.
Secondly, I don’t see why Axe needed to come up with a conversion factor from the peak in your Figure 3 to the peak in Figure 1. I don’t see what that would accomplish, to get an estimate of the percentage of functional variants generated from the wild-type enzyme, to have this along with the estimate for the disabled enzyme variants. Axe’s aim was to estimate “the Prevalence of Protein Sequences Adopting Functional Enzyme Folds” in general, so having two samples instead of one wouldn’t seem to be helpful or necessary.
Then you write that “Anyone who has plated transformed E. coli on ampicillin or other beta-lactams knows that this isn’t a very quantitative method, and certainly not suited to quantitatively distinguishing enzyme variants with differing activities.” Yet here I read: “Volume Accuracy: Ensuring the precise volume of the sample is critical for certain quantitative analyses.” Which implies you have to be very careful, but it can be done. Similarly here: “The standard plate count is a reliable method for enumerating bacteria and fungi.” They continue: “Accuracy in quantitation is determined by accurate pipette use and adequate agitation of dilution tubes.” Implying quantification can be done accurately.
Then you state: “More to the point of the JMB paper, Axe’s BioComplexity paper shows that, in cases where enzyme activity may be very low, this assay cannot reliably distinguish between low and zero enzyme activity. This is very important – I believe the conditions used by Axe in the 2004 JMB paper cannot distinguish between mutants with low but significant activities and those with no activity. In other words, the accuracy of Axe’s estimates in the 2004 paper cannot be known, and he may be wrong by tens and tens of orders of magnitude or more.”
So I went through this paper, and couldn’t find any statement along the lines of “where enzyme activity may be very low, this assay cannot reliably distinguish between low and zero enzyme activity.” Could you quote the relevant section?